SCHEMBL5228042

SCHEMBL5228042

O=C(O)Cc1ccccc1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.79
DPP4 P27487 1/20 0.58
SUCNR1 Q9BXA5 2/20 0.54
ALDH1A1 P00352 2/20 0.54
ADRB2 P07550 1/20 0.54
FFAR1 O14842 1/20 0.54
PNLIP P16233 1/20 0.52
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52
PTGDR2 Q9Y5Y4 2/20 0.52
FLT1 P17948 1/20 0.52
KDR P35968 1/20 0.52
SMO Q99835 1/20 0.51
NR1H4 Q96RI1 1/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12700237 0.81 BCAT2 (0.73) BCAT2DPP4ALDH1A1ADRB2FFAR1
SCHEMBL16088833 0.81 BCAT2 (0.73) BCAT2DPP4ALDH1A1ADRB2FFAR1
SCHEMBL16088715 0.80 BCAT2 (0.71) BCAT2DPP4ALDH1A1ADRB2FFAR1
SCHEMBL7820643 0.79 ALDH1A1 (0.76) ALDH1A1PNLIPMEN1KMT2ASMO
SCHEMBL5632774 0.78 SMN1; SMN2 (0.62) SUCNR1ALDH1A1MEN1POLBKMT2A
SCHEMBL2117583 0.77 SMO (0.75) PNLIPMEN1POLBHPGDKMT2A
SCHEMBL2698725 0.76 PNLIP (0.82) ALDH1A1PNLIPMEN1POLBHPGD
SCHEMBL1197196 0.75 TMPRSS4 (0.57) BCAT2ALDH1A1ADRB2MEN1KMT2A
SCHEMBL10445131 0.75 BCAT2 (0.60) BCAT2SUCNR1ALDH1A1MEN1HPGD
SCHEMBL5630776 0.75 ATM (0.62) BCAT2ALDH1A1MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 BCAT2 230/4885DPP4 829/4885SUCNR1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.